Biomarkers for Early Detection of Alzheimer Pathology
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The increasing prevalence of Alzheimer's disease and the devastating consequences of late-life dementia motivates the drive to develop diagnostic biomarkers to reliably identify the pathology associated with this disorder. Strategies to accomplish this include the detection of altered levels of tau and amyloid in cerebrospinal fluid, the use of structural MRI to identify disease-specific patterns of regional atrophy and MRI T(1)rho to detect disease-related macromolecular protein aggregation, and the direct imaging of amyloid deposits using positron emission tomography and single photon emission computerized tomography. Success will facilitate the ability to reliably diagnose Alzheimer's disease while the symptoms of brain failure are mild and may provide objective measures of disease-modifying treatment efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 1×
“AD is the major cause of late-life dementia in the United States, with an increasing personal, social and economically devastating burden associated with the steady growth of the number of individuals living into the eighth and ninth decade of life [”
BackgroundHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036
Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study
Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y. F., Hotton, G., Cutler, D., Fox, N., Kennedy, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000244749.20056.d4 · Cited by 518
One-year Age Changes in MRI Brain Volumes in Older Adults
Resnick, S. M. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.5.464 · Cited by 517 · cited 1×
“While helpful in supporting a diagnosis of AD, this approach is confounded by the presence of atrophy due to other pathological processes and the generalized atrophy that occurs as part of normal aging [”
BackgroundClark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357
Self-citation
Cited by
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationThe Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,010
Self-citationAmyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986
Schuff, N., Woerner, N., Boreta, L., Kornfield, T., Shaw, L. M., Trojanowski, J. Q., Thompson, P. M., Jack, C. R., Weiner, M. W., & Initiative, T. A. D. N. (2008) · Brain · doi:10.1093/brain/awp007 · Cited by 679
Self-citationThe Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans
Weiner, M. W., Aisen, P. S., Jack, C. R., Jagust, W. J., Trojanowski, J. Q., Shaw, L., Saykin, A. J., Morris, J. C., Cairns, N., Beckett, L. A., et al. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.007 · Cited by 599
Self-citationThe Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.09.172 · Cited by 476
Self-citationImaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L., & Rowe, C. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.9 · Cited by 441
Joshi, A. D., Pontecorvo, M. J., Clark, C. M., Carpenter, A. P., Jennings, D. L., Sadowsky, C. H., Adler, L. P., Kovnat, K. D., Seibyl, J. P., Arora, A., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.090340 · Cited by 391
Self-citationWeiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348
“In tandem with the development of these biomarkers, a new imaging technology using 11C-PiB in PET scans was being developed [27,28], and the possibility of a diagnostic approach predicated on the concept of certain combinations of biomarkers providing complementary information was raised [8,26].”
BackgroundMethodInfluentialSelf-citationRowe, C. C., & Villemagne, V. L. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.076315 · Cited by 261
Cui, Y., Liu, B., Luo, S., Zhen, X., Fan, M., Liu, T., Zhu, W., Park, M., Jiang, T., Jin, J. S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021896 · Cited by 236
“Some studies [6,52] have reported similar results.”
Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans
Hua, X., Hibar, D. P., Lee, S., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.033 · Cited by 234
CSF Biomarkers for Alzheimer's Disease Diagnosis
Anoop, A., Singh, P. K., Jacob, R. S., & Maji, S. K. (2010) · International Journal of Alzheimer's Disease · doi:10.4061/2010/606802 · Cited by 193
“The loss of brain volume is one of the consequences of AD neurodegeneration [11, 21], and it could be differentiated from normal brain by using computerized tomography (CT) and magnetic resonance imaging (MRI) techniques [23].”
BackgroundImpaired default network functional connectivity in autosomal dominant Alzheimer disease
Chhatwal, J. P., Schultz, A. P., Johnson, K., Benzinger, T. L. S., Jack, C., Ances, B. M., Sullivan, C. A., Salloway, S. P., Ringman, J. M., Koeppe, R. A., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a1aafe · Cited by 179
Tau and p-tau as CSF biomarkers in dementia: a meta-analysis
van Harten, A. C., Kester, M. I., Visser, P.-J., Blankenstein, M. A., Pijnenburg, Y. A. L., van der Flier, W. M., & Scheltens, P. (2011) · cclm · doi:10.1515/cclm.2011.086 · Cited by 167
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?
Jellinger, K. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0466-z · Cited by 60
“A combination of the best CSF and MRI data will lead to a more precise diagnostic prediction [93,94], and will be further increased by using multimodal techniques and novel CNS biomarkers [20,95-97], but histopathology is still considered to add to premortem diagnostic accuracy [98].”
BackgroundAdvanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease
Rani, S., Dhar, S. B., Khajuria, A., Gupta, D., Jaiswal, P. K., Singla, N., Kaur, M., Singh, G., & Barnwal, R. P. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01330-y · Cited by 48
Cortical signatures of cognition and their relationship to Alzheimer’s disease
Initiative, F. T. A. D. N., Gross, A. L., Manly, J. J., Pa, J., Johnson, J. K., Park, L. Q., Mitchell, M. B., Melrose, R. J., Inouye, S. K., & McLaren, D. G. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9180-5 · Cited by 25
Metadata
- Authors
- Clark, C. M., Davatzikos, C., Borthakur, A., Newberg, A., Leight, S., Lee, V. M.-Y., & Trojanowski, J. Q.
- Venue
- Neurosignals
- Publisher
- S. Karger AG
- Published
- 2007-12-05
- Volume
- 16
- Issue
- 1
- Pages
- 11-18
- ISSN
- 1424-862X (ISSN-L)
- 1424-8638
- OpenAlex
- W2002923218
- Cited by
- 94
- References
- 7
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.